Patent classifications
C07D307/85
INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
Selective D.SUB.3 .dopamine receptor agonists and methods of their use
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.
Selective D.SUB.3 .dopamine receptor agonists and methods of their use
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.
NOVEL COMPOUNDS AS INHIBITORS OF PCSK9
Disclosed are a compound of formula (I), wherein the variables are defined in the specification, a pharmaceutical composition containing the same, and a method and a use of the compound or composition in the treatment of a PCSK9-mediated disease such as cardiovascular disease.
##STR00001##
NOVEL COMPOUNDS AS INHIBITORS OF PCSK9
Disclosed are a compound of formula (I), wherein the variables are defined in the specification, a pharmaceutical composition containing the same, and a method and a use of the compound or composition in the treatment of a PCSK9-mediated disease such as cardiovascular disease.
##STR00001##
HETEROAROMATIC ACETAMIDE DERIVATIVE, AND PREPARATION AND USE THEREOF
Provided in the present invention are a heteroaromatic acetamide derivative and the preparation and the use thereof, wherein the heteroaromatic acetamide derivative is a heteroaromatic acetamide compound as shown in general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. According to the present invention, experiments have confirmed that the heteroaromatic acetamide derivative of the present invention can specifically bind to transient receptor potential ankyrin 1 (TRPA1) and inhibit or reduce the activity thereof, and can be used for treating diseases mediated by TRPA1. The present invention further provides a method for preparing the heteroaromatic acetamide derivative, and a drug and pharmaceutical composition containing the heteroaromatic acetamide derivative.
##STR00001##
SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING
Certain embodiments describe antiviral compounds and related methods of using such compounds.
SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING
Certain embodiments describe antiviral compounds and related methods of using such compounds.
NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES
The invention provides novel compounds having the general formula (I)
##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as described herein, compositions including the compounds and methods of using the compounds.
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.